I-SQUARED-CAPITAL
9.12.2020 17:02:08 CET | Business Wire | Press release
I Squared Capital, through its ISQ Global Infrastructure Fund II, has acquired and combined Infofabrica Holdings Pte Ltd and Cloud Kinetics Tech Pte Ltd, two Cloud migration services companies based in Singapore. The combined businesses are poised to become a leading Cloud migration and managed services provider in Southeast Asia and India, providing capability across all major public Cloud operators. These investments are part of a new Asian Digital Infrastructure platform and will enable I Squared Capital’s Digital Infrastructure companies to offer comprehensive Cloud-based solutions to their customers. The Cloud platform will have a growing pool of over 300 professionals with deep experience in Cloud infrastructure, data, analytics, application modernization and Cloud management and possess a broad range of Cloud certifications.
“The future of data and computing will be driven by the corporate adoption of hybrid Cloud solutions through an orchestrated mix of on-premises infrastructure, co-location and Cloud services. Offering seamless and efficient migration to the hybrid Cloud relieves a critical bottleneck to Cloud adoption, especially in the Asia-Pacific region. The combination of Infofabrica and Cloud Kinetics will result in a powerful Cloud migration solution provider for our clients,” said Gautam Bhandari, Managing Partner of I Squared Capital. “With these acquisitions, our global investments and commitments to the Digital Infrastructure sector are over $2.6 billion and growing.”
Cloud migration consists of the specialized capabilities and technologies, undertaken by certified experts, to enable businesses to move to and operate on the Cloud seamlessly. IDC predicts that Southeast Asia’s Cloud computing market will reach $40 billion by 2025, underscoring its importance in our daily lives. The platform is co-founded and being led by Haji Munshi, a technology executive who has held senior leadership positions at Google Cloud, Cisco, Hewlett Packard Enterprise and Dell, and Tameem Ebrahim, ex-Founding Partner of Quvat Capital and was an investment banker at Merrill Lynch and Deutsche Bank in Southeast Asia.
“The debate on the need for Cloud has ended after the experience of the Covid-19 pandemic,” said Haji Munshi, Group CEO of InfoFabrica and Cloud Kinetics. “Whether businesses are developing and testing their new applications, scaling their online e-commerce offerings, or running their core business workloads, this is possible only because of the stable, scalable solutions offered by the public Cloud. The demand for technical capability to migrate to Cloud has far outstripped supply in Asia-Pacific thus far and the combined company will be a market leader in Cloud migration services.”
“We are really pleased to be partnering with I Squared Capital, their expertise and breadth in Asia, along with existing large-scale investments in telecoms and data centers, will certainly accelerate and move us closer to our vision to be the top cloud migration and managed services provider in the region,” commented Abu Bakar Mohd Nor, Chairman of IFF. “The complementary capabilities of InfoFabrica and Cloud Kinetics is key and part of our strategy to be an end-to-end Cloud specialist and also simplify our clients’ Cloud migration journey.”
About Infofabrica Holdings (https://www.infofabrica.com/ ): Founded in 2013, InfoFabrica Holdings Pte Ltd has operations in Singapore, Indonesia, Vietnam and Malaysia. InfoFabrica is a certified Cloud partner of Amazon Web Services, Google Cloud, IBM Cloud.
About Cloud Kinetics (https://www.Cloud-kinetics.com/ ): Founded in 2012, Cloud Kinetics Tech Pte Ltd has operations in Singapore, Thailand, India and the United States. Cloud Kinetics is a certified Cloud partner of Microsoft Azure, Amazon Web Services and Google Cloud.
About I Squared Capital (http://www.isquaredcapital.com/ ): I Squared Capital is an independent global infrastructure investment manager focusing on energy, utilities, digital infrastructure, transport and social infrastructure in the Americas, Europe and Asia. The firm has offices in Miami Hong Kong, London, New Delhi, New York, and Singapore.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005751/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom